US · NVNO
enVVeno Medical Corporation
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Irvine, CA 92618
- Website
- envveno.com
Price · as of 2024-12-31
$10.50
Market cap 165.03K
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $0.00 | ||||
| 2017 | $0.00 | $889,136.54 | |||
| 2018 | $1,233.75 | $142,133.67 | $0.00 | $0.00 | $1,928,423.27 |
| 2019 | $481.25 | $149,623.92 | $0.00 | $0.00 | $1,057,963.48 |
| 2020 | $239.75 | $4,020.31 | |||
| 2021 | $173.60 | ||||
| 2022 | $175.77 | ||||
| 2023 | $220.85 | ||||
| 2024 | $107.45 |
AI valuation
Our deep-learning model estimates enVVeno Medical Corporation's (NVNO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $10.50
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NVNO | enVVeno Medical Corporati… | $10.50 | 165.03K | — | — | — | — | -0.07 | 0.04 | — | 1.91 | — | 0.04 | 0.00% | — | — | -49.39% | -3781.90% | -46.63% | 0.03 | — | 20.88 | 20.60 | 0.03 | -3351.00% | — | -1067.00% | -1122.35% | -8.04 | -2678.57% | 0.00% | 0.00% | 0.00% | 1.70 | 2.41 | — | -5.04 |
| ADGM | Adagio Medical Holdings, … | $1.00 | 15.22M | +1,418% | -58% | — | +543% | -0.21 | 0.81 | 59.89 | -0.19 | — | -15.73 | -620.07% | -23226.77% | -19986.25% | 133.87% | 157.35% | -271.53% | 0.82 | 56.70 | 3.27 | 2.66 | 0.07 | -2716.00% | -1033.00% | 1971.00% | -193.09% | -3.79 | 78.34% | 0.00% | 0.00% | 256.59% | -0.19 | -0.38 | 43.83 | -5.52 |
| AEMD | Aethlon Medical, Inc. | $2.01 | 1.53M | — | — | — | — | -0.31 | 0.80 | — | 0.06 | -0.40 | 0.80 | 0.00% | — | — | -245.88% | -1215.78% | -171.58% | 0.13 | -924.06 | 3.13 | 2.90 | 0.37 | 7654.00% | — | -2635.00% | -185.54% | -4.03 | -995.06% | 0.00% | 0.00% | 8.49% | 0.08 | 0.10 | — | -34.37 |
| ALUR | Allurion Technologies Inc… | $1.17 | 9.09M | +15,409% | -17% | — | +29,866% | -0.21 | -0.07 | 0.17 | -1.26 | — | -0.07 | 66.97% | -156.33% | -81.43% | 35.22% | 82.22% | -50.03% | -0.49 | -22.17 | 1.44 | 1.19 | -1.02 | -7987.00% | -3994.00% | -3457.00% | -785.83% | -2.24 | 70.29% | 0.00% | 0.00% | 0.00% | -0.56 | -0.65 | 0.87 | -13.22 |
| AYTU | Aytu BioPharma, Inc. | $2.57 | 20.82M | +791% | +627% | — | — | -1.04 | 0.74 | 0.21 | -1.31 | — | -0.61 | 69.04% | -11.79% | -20.43% | -58.10% | -44.62% | -11.16% | 1.21 | -2.11 | 1.26 | 0.98 | 1.72 | -2448.00% | 184.00% | 20082.00% | -36.55% | -0.03 | -29.45% | 0.00% | 0.00% | 31.33% | -0.78 | -1.18 | 0.09 | -3.20 |
| COCH | Envoy Medical, Inc. | $0.72 | 15.07M | +3,147% | -23% | — | +2,867% | -1.16 | -1.39 | 116.08 | -2.03 | — | -1.39 | -229.78% | -8558.22% | -9242.22% | 217.79% | 381.46% | -226.68% | -1.04 | -23.60 | 1.24 | 0.84 | -0.72 | -4134.00% | -2880.00% | 977.00% | -72.47% | -2.38 | 374.98% | 9.37% | -10.90% | 9.37% | -2.09 | -2.13 | 179.09 | -39.33 |
| CODX | Co-Diagnostics, Inc. | $2.30 | 2.57M | +1,244% | +270% | — | +1,660% | -13.54 | 9.38 | 130.17 | -12.45 | -406.20 | 18.07 | 74.48% | -1023.75% | -961.37% | -53.65% | -140.21% | -47.25% | 0.04 | — | 4.41 | 4.08 | 0.02 | 333.00% | -4253.00% | 2754.00% | -5.87% | -3.99 | -104.61% | 0.00% | 0.00% | 0.00% | -12.03 | -16.12 | 123.12 | 29.30 |
| EKSO | Ekso Bionics Holdings, In… | $10.14 | 24.6M | +55% | -60% | — | +814% | -2.12 | 2.75 | 1.94 | -2.68 | -0.27 | 4.87 | 53.48% | -104.12% | -91.37% | -107.62% | -117.46% | -50.02% | 0.29 | -43.13 | 1.63 | 0.98 | -0.15 | 77679.00% | -2860.00% | 2131.00% | -48.31% | -1.37 | -105.67% | 0.91% | -1.90% | 0.91% | -1.97 | -2.19 | 2.05 | -18.15 |
| GOVX | GeoVax Labs, Inc. | $1.60 | 1.62M | — | +969% | — | — | -0.35 | 1.76 | 2.24 | -0.14 | — | 1.78 | 97.59% | -635.83% | -631.98% | -462.31% | 4381.85% | -286.62% | 0.00 | -1176.34 | 2.55 | 1.98 | 0.22 | -5284.00% | — | -209.00% | -278.43% | -7.94 | 4303.75% | 0.00% | 0.00% | 0.00% | -0.13 | -0.14 | 0.85 | -29.47 |
| PRPH | ProPhase Labs, Inc. | $0.15 | 710.55K | +15,560% | +1,020% | — | +135,988% | -1.62 | 10.90 | 11.84 | -3.22 | -0.97 | -10.50 | -2.22% | -570.59% | -788.24% | -174.58% | -79.42% | -63.85% | 3.34 | -11.53 | 0.95 | 0.65 | -0.74 | 16633.00% | -8475.00% | 2717.00% | -23.02% | -0.55 | -37.92% | 0.00% | 0.00% | 0.00% | -2.69 | -5.64 | 15.37 | -2.37 |
| VVOS | Vivos Therapeutics, Inc. | $1.40 | 8.25M | +1,347% | +8,020% | — | — | -1.66 | 2.33 | 1.23 | -1.31 | — | 3.91 | 60.00% | -74.32% | -74.09% | -266.25% | -562.91% | -85.62% | 0.19 | — | 1.50 | 1.34 | 0.45 | -8007.00% | 891.00% | 400.00% | -71.58% | -2.55 | -668.13% | 0.00% | 0.00% | 27.53% | -1.23 | -1.04 | 0.92 | -9.26 |
About enVVeno Medical Corporation
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
- CEO
- Robert A. Berman
- Employees
- 37
- Beta
- 1.10
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $10.50) − 1 = — (DCF, example).